Dei BioPharma Ltd: Leading Africa in Pharmaceuticals Research and Innovation
Dei BioPharma Ltd is a biotech and pharmaceutical research firm duly incorporated in Uganda, specializing in the development and manufacture of innovative medicines and vaccines.
Under the leadership of Dr. Magoola Matthias, the Founder, Dei BioPharma, is investing in novel research and owns over 100 patents filed with the United States Patent and Trademark Office (USPTO) that cover its technology.
The firm is currently engaged in the development of an iconic Drugs and Vaccines Manufacturing Facility that was commissioned in July 2021 by President Yoweri Museveni and Kenya President William Ruto (then Vice President).
The state-of-the-art facility is situated in Matugga, Wakiso district, near Kampala- Uganda, and sitting on a campus of over 250-acres of land , shall produce high-quality medicines across a wide range of therapeutic areas powered by about 30 manufacturing units.
What we produce
Our primary focus at Dei BioPharma is to discover new drugs and medicines. A vital process since drug resistance is a global challenge and causing deaths to millions in the world.
These include Malaria, HIV-Aids, Cancer, Generics, Beta-lactams, Non beta-lactams, Hormones, Liquids, Nutraceuticals, Parenterals, Heparin, APIs, Insulin glargine, Vaccines, Cephalosporins, Monoclonal antibodies, mRNA based therapeutics.
The manufacturing facility is gearing to produce one billion doses of mRNA vaccines and key biological drugs guided by the most stringent Global GMP, including the US FDA, EU (EMA) and the World Health Organization (WHO) standards.
Dei BioPharma will create more than 40,000 professional jobs, especially for scientists and other professions for the Uganda economy.